RAP.AU · ResApp Health Limited

-

Please sign in to comment on RAP.AU

1 Comment

Admin

4 years, 1 month ago

ResApp Health Limited is currently in a long term downtrend where the price is trading 39.9% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

ResApp Health Limited's total revenue rose by 128.2% to $59K since the same quarter in the previous year.

Its net income has increased by 18.1% to $-3M since the same quarter in the previous year.

Finally, its free cash flow fell by 102.3% to $-2M since the same quarter in the previous year.

Based on the above factors, ResApp Health Limited gets an overall score of 3/5.

CurrencyCode	AUD
ISIN	AU000000RAP5
Sector	Healthcare
Industry	Health Care Technology
Exchange	AU

Beta	-0.42
Target Price	0.24
Dividend Yield	0.0%
Market Cap	176M
PE Ratio	None

ABOUT

ResApp Health Limited

ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease. The company offers ResAppDx, a smartphone-based acute respiratory disease diagnostic test; and SleepCheckRx, a smartphone application for at-home sleep apnoea screening. Its technology uses mathematical features for the diagnosis of pneumonia, asthma, and chronic obstructive pulmonary disease. The company was formerly known as Narhex Life Sciences Limited. ResApp Health Limited was incorporated in 2000 and is headquartered in Brisbane, Australia. As of September 15, 2022, ResApp Health Limited operates as a subsidiary of Pfizer Australia Holdings Pty Limited.

RAP.AU · ResApp Health Limited

-

ResApp Health Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest ResApp Health Limited using a moving average strategy